Opinion|Videos|February 10, 2025
Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients
Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Advertisement
Video content above is prompted by the following:
- How do the treatment options evolve as a child ages?
- FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, abrocitinib ≥ 12 years, upadacitinib ≥ 12 years) vs off-label use
- How can the use of these systemic agents in pediatric patients potentially mitigate the atopic march? What can we do to halt the progression of pediatric atopic diseases?
- Lin 2024: A cohort taking dupilumab showed a significant risk reduction in atopic march (HR, 0.60 for developing asthma; HR, 0.69 for developing allergic rhinitis) in patients 18 years or younger vs conventional immunomodulatory care without dupilumab.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Neurodevelopmental disorder risks not increased by prenatal acetaminophen use
2
Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis
3
FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury
4
Valeria Cohran, MD, highlights specialist-pediatrician collaboration when treating short bowel syndrome-associated intestinal failure
5
